Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q1 2019 Earnings Presentation
9 slides from Arcadia Biosciences's earnings presentation, May 8, 2019
Slide 1: Q1 2019 Financial Results and Business Highlights
Q1 2019 Financial Results and Business Highlights May 8, 2019
Slide 2: Forward-looking statements
Forward-looking statements • “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the com
Slide 3: GoodWheat production scales in preparation for commercial launch
GoodWheatTM production scales in preparation for commercial launch • Completed counter-season production, now being harvested • Building supply for commercial launch, first sales expected in 2019 • Preparations underway for planting in the summer season in the key wheat growing states • GoodWheat pr
Slide 4: Verdeca introduced pre-commercial HB4 soybeans to growers at Expoagro in Argentina
Verdeca introduced pre-commercial HB4 soybeans to growers at Expoagro in Argentina • Expoagro is Argentina’s largest farm show – more than 1200 growers visited the Verdeca pavilion • Verdeca Bio-Innovator program provides growers with priority access to test HB4 soybean varieties in their fields • H
Slide 5: Arcadia Specialty Genomics
Arcadia Specialty Genomics TM
Slide 6: Addressing the need for quality genetics, product reliability and supply assurance in the burgeoning cannabis industry
Addressing the need for quality genetics, product reliability and supply assurance in the burgeoning cannabis industry • Market leaders recognize the need for improved standards and quality in cannabis consumer products • Mislabeling, unsubstantiated health claims, and lack of quality standards are
Slide 7: Initial plantings at Hawaii hemp research station are flourishing
Initial plantings at Hawaii hemp research station are flourishing • Evaluating performance and quality attributes against climate and geographic conditions • Demonstrating compliance with regulatory requirements and standards • Staggering additional research and multiple harvests to accelerate resea
Slide 8: Arcadia Specialty Genomics research goals for 2019
Arcadia Specialty GenomicsTM research goals for 2019 • Germplasm strategy - Build experience with geographic and phenotypical diversity among the most productive and highest quality strains available • Hemp breeding - Leverage research programs in HI and CA to improve agronomic performance and build
Slide 9: Key financial results
Key financial results First Quarter $ Favorable/ % Favorable/ 2019 2018 (Unfavorable) (Unfavorable) Total revenues 158 214 (56) (26%) Cost of product revenues 59 36 (23) (64%) R&D expense 1,505 1,396 (109) (8%) SG&A expense 2,812 2,621 (191) (7%) Total operating expenses 4,376 4,053 (323) (8%) Loss